期刊
ASIA-PACIFIC JOURNAL OF ONCOLOGY NURSING
卷 8, 期 6, 页码 604-609出版社
ELSEVIER SCIENCE INC
DOI: 10.4103/apjon.apjon-2136
关键词
Immune-related adverse events; immunotherapy; oral mucositis; quality of life
类别
Recent introduction of immune checkpoint inhibitors has shown significant improvement in cancer treatment outcomes by targeting key immune checkpoints. However, these inhibitors can also lead to immune-related adverse events, including oral reactions, which require early recognition and intervention for improved patient quality of life. Further research is needed on oral irAEs as literature focusing on them is limited.
Recent advent of immune checkpoint inhibitors (ICIs) have made significant improvement in the treatment outcome of cancer patients. They are also known to increase the overall survival in many malignancies. They target key immune checkpoints, acting on the cytotoxic T-lymphocyte antigen-4, programmed death-1 (PD-1), and PD-1 ligand 1 pathways. ICIs are effective in cancer therapy, but also possess various adverse effects that are termed together as immune-related adverse events (irAEs). Information focusing only on the oral reactions of irAEs is scanty in the literature. Therefore, we performed a computerized database search in PubMed and Google Scholar to identify and collect data regarding the oral adverse effects of ICIs. The early recognition of oral irAEs and appropriative intervention may help in improving the quality of life in patients. This paper presents a brief review of oral irAEs and their management.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据